Genolution

제놀루션 · 225220

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$21.6M (₩29.8B)

Overview

Genolution makes diagnostic tools that detect genetic material, such as DNA and RNA, from human samples like blood, urine, and swabs, enabling laboratories to identify infectious diseases, cancers, and hereditary conditions.

Its products include reagents that extract nucleic acids from samples and automated instruments that perform that extraction, supplied to clinical and research settings. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company runs two distinct business lines: molecular diagnostics devices and products and services related to RNAi (RNA interference, a gene-silencing research technique).

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$6.8M
▲ +31.8% YoY
Operating profit · FY2025
−US$6.3M
Loss narrowed
Net income · FY2025
−US$9.1M
Loss widened

Revenue

  • FY2023US$7.1M
  • FY2024US$5.2M
  • FY2025US$6.8M

Operating profit

  • FY2023−US$5.1M
  • FY2024−US$6.6M
  • FY2025−US$6.3M

Net income

  • FY2023−US$4M
  • FY2024−US$5.2M
  • FY2025−US$9.1M

Key ratios (FY2025)

ROE
-18.6%
Debt/Eq
38.2%
Op. margin
-91.9%
Net margin
-133.9%
Rev. YoY
▲ +31.8%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.